Target CML

Consider an earlier switch for patients with intolerance and/or suboptimal response.

Patients with intolerance may need a treatment switch. Some persistent side effects can impact compliance with therapy, which in turn can lead to poor outcomes.^7,8

Patients who experience suboptimal response may need a different treatment strategy.^2,9,10

See data on why earlier treatment switching should be considered

Learn more

Assess patient scenarios and review guideline recommendations

Explore patient profiles

Review videos from CML experts, patients, and more

Watch videos

ATP, adenosine 5’-triphosphate; CML, chronic myeloid leukemia; TKI, tyrosine kinase inhibitor.

References: 1. Soverini S, Gnani A, Colarossi S, et al. Blood. 2009;114(10):2168-2171. 2. Garg RJ, Kantarjian H, O'Brien S, et al. Blood. 2009;114(20):4361-4368. 3. Ibrahim AR, Paliompeis C, Bua M, et al. Blood. 2010;116(25):5497-5500. 4. Gambacorti-Passerini C, Brümmendorf TH, Kim D-W, et al. Am J Hematol. 2014;89(7):732-742. 5. Shah NP, Kim D-W, Kantarjian H, et al. Haematologica. 2010;95(2):232-240. 6. Kantarjian HM, Giles FJ, Bhalla KN, et al. Blood. 2011;117(4):1141-1145. 7. Marin D, Bazeos A, Mahon F-X, et al. J Clin Oncol. 2010;28(14):2381-2388. 8. Kim D-W, Saussele S, Williams LA, et al. Ann Hematol. 2018;97(8):1357-1367. 9. Bosi GR, Fogliatto LM, Costa TEV, et al. Hematol Transfus Cell Ther. 2019;41(3):222-228. 10. Iacob RE, Zhang J, Gray NS, Engen JR. PLoS One. 2011;6(1):e15929.

Why Consider Switching

Patient Profiles

Expert Videos and More

Consider an earlier switch for patients with intolerance and/or suboptimal response.